Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ETSOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will participate in a Virtual Fireside Chat hosted by Chardan C ...

Summary of Scenti Biosciences Conference Call Company Overview - **Company**: Scenti Biosciences - **Industry**: Biotechnology - **Focus**: Development of cell and gene therapies for incurable diseases using a synthetic biology platform called GeneCircuits [1][2] Core Technology and Product Development - **Technology**: Logic gating technology allows targeting of previously untreatable cancers, enhancing precision and control in therapy [3][4] - **Lead Program**: Santi 202, targeting relapsed/refractory Acute Myeloid Leukemia (AML) and related cancers, currently in early-stage clinical trials [4][5] - **Manufacturing**: Scalable off-the-shelf manufacturing streamlines treatment for patients [5] Clinical Data and Efficacy - **Clinical Results**: Positive data reported at AACR 2025 meeting, with five patients achieving overall response rate (ORR) and four achieving complete response [15] - **Durability**: Longest-term patient response lasted over eight months, indicating potential for outpatient use [14][15] - **Patient Population**: AML affects over 20,000 newly diagnosed patients annually, with a 60% relapse rate within 12 months [10] Mechanism of Action - **Logic Gates**: Designed to differentiate between cancerous and healthy cells, minimizing toxicity [7][8] - **Cell Engineering**: Utilizes natural killer (NK) cells genetically modified to express proteins targeting AML cells while protecting healthy cells [11][12] - **Key Proteins**: Includes activating CAR (ACAR) targeting CD33 and FLT3, and an inhibitory CAR that protects healthy cells [12][13] Clinical Trial Design - **Phase One Trial**: Multicenter, multinational study assessing two dose levels (1 billion and 1.5 billion CAR positive NK cells) [16][17] - **Dosing Schedule**: Patients receive multiple doses, with assessments for response at 28 days [18] Safety and Tolerability - **Patient Monitoring**: Recovery of healthy blood cell counts observed post-treatment, indicating maintenance of healthy bone marrow [22][23] - **Toxicity Management**: Logic gating technology aims to reduce toxicity associated with traditional therapies [7][8] Future Directions - **Expansion Plans**: Focus on increasing patient numbers and showcasing the efficacy of logic gating technology [30][31] - **Broader Applications**: Potential to apply logic gating technology to solid tumors and other cancer types [25][28] Competitive Landscape - **Differentiation**: Scenti's approach is agnostic to genetic mutations, providing a complementary mechanism to existing therapies targeting genetic mutations in AML [32] - **Comparison with CAR T**: NK cells are preferred for AML due to their rapid action and safety profile, while T cells may be more suitable for solid tumors [33][34] Conclusion - **Outlook**: Scenti Biosciences is positioned to advance its lead program Santi 202 and explore broader applications of its technology in the oncology space, with ongoing clinical trials and promising early results [27][28]

Live webcast on Thursday, May 29th at 2:40 PM ETSOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursda ...

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported the receipt of an additional $1.0 million from the California Institute of Regenerative Medicine (CIRM) upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant t ...

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Senti announced in a press release issued on April 28, 2025, that "enrollmen ...

Senti Biosciences (SNTI) 2025 Conference May 08, 2025 01:00 PM ET Speaker0 Are you ready to kick it off? Yeah. Whenever you guys wanna do. Speaker1 Okay. Welcome back to the Citizens Life Science Conference. My name is Silvan Turca, and I'm a senior analyst covering precision medicines. And now it's my pleasure to introduce Sandi Biosciences. Presenting will be Tim Liu, CEO and cofounder, and Jay Cross, CFO. Thank you so much for coming and joining us today. Speaker0 Well, thanks a lot, Silvan. Appreciate t ...

Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuitAccess video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from ___to___ Commission File Number 001-40440 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Clinical Trial Results - Senti Bio reported that 5 of 7 evaluable patients achieved an overall response rate (ORR) of 71.4%, including 3 complete remissions (CR) and 1 complete remission with partial hematologic recovery (CRh) in the SENTI-202 trial[1] - All complete remission (cCR) patients in the trial were measurable residual disease (MRD) negative, indicating effective treatment[3] - The Phase 1 study of SENTI-202 is ongoing, with continued enrollment to confirm the preliminary RP2D[4] - Senti Bio is collaborating with Celest Therapeutics to evaluate SENTI-301A in a trial in China, although enrollment has been stopped due to observed dose limiting toxicities[11] - The company plans to present additional data on SENTI-202 at the AACR meeting, highlighting its potential as a treatment for AML[6] Financial Performance - As of March 31, 2025, Senti Bio held cash and cash equivalents of approximately $33.8 million[10] - Research and development expenses for Q1 2025 were $9.3 million, an increase of 5.7% from $8.8 million in Q1 2024[10] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024, primarily due to a reduction in personnel-related expenses[14] - The net loss for the quarter ended March 31, 2025, was $14.1 million, equating to $1.41 per basic and diluted share[14] Strategic Outlook - Senti Bio's growth strategy includes ongoing clinical trials and potential future research and development efforts[18] - The company is currently conducting a Phase 1 clinical trial for SENTI-202, with expectations for data availability and patient dosing timelines[17] - Senti Bio's management emphasizes the uncertainty surrounding future results due to various risks and market conditions[18] Risks and Dependencies - The company acknowledges dependence on third parties for clinical trial activities and GMP manufacturing, which may impact timelines[18] - Macroeconomic factors, including inflation and rising interest rates, are noted as potential risks to business operations[18] - Senti Bio's forward-looking statements are subject to change based on subsequent events and developments[18] Communication and Investor Relations - The company encourages stakeholders to review information posted on its website and social media for material updates[19] - Senti Bio's communication strategy includes regular updates through its website and social media platforms[19] - The company has not committed to updating forward-looking statements unless required by law[18] - Investor inquiries can be directed to JTC Team, LLC for further information[20]

Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 do ...